Akebia Therapeutics
AKBA
114 hedge funds and large institutions have $104M invested in Akebia Therapeutics in 2024 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 26 increasing their positions, 25 reducing their positions, and 13 closing their positions.
208% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 13
46% more call options, than puts
Call options by funds: $2.88M | Put options by funds: $1.97M
42% more capital invested
Capital invested by funds: $73.5M → $104M (+$30.8M)
31% more funds holding
Funds holding: 87 → 114 (+27)
4% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 25
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.18% less ownership
Funds ownership: 29.42% → 27.24% (-2.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$3.21M |
| 2 |
Goldman Sachs
New York
|
+$2.15M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$1.64M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$1.26M |
| 5 |
Millennium Management
New York
|
+$1.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
Alerce Investment Management
Chicago,
Illinois
|
-$4.8M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$2.57M |
| 3 |
Renaissance Technologies
New York
|
-$1.8M |
| 4 |
BlackRock
New York
|
-$933K |
| 5 |
Morgan Stanley
New York
|
-$894K |
AKBA Hedge Fund Activity: Q1 2024 in Review
114 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q1 2024, worth a combined $104M — up 42% from $73.5M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new AKBA positions and 13 closed out — a net gain of 27 holders — while 26 added to existing stakes and 25 trimmed.
The largest buyer was Qube Research & Technologies (QRT), adding an estimated $3.21M. The largest seller was Alerce Investment Management, cutting an estimated $4.8M.
- 114 institutional investors held Akebia Therapeutics (AKBA) as of Q1 2024, up from 87 in Q4 2023.
- Funds reported $104M of Akebia Therapeutics stock for Q1 2024, up 42% quarter-over-quarter.
- 40 funds opened new Akebia Therapeutics positions in Q1 2024 and 13 closed out, a net change of +27 holders.
- The largest Akebia Therapeutics buyer in Q1 2024 was Qube Research & Technologies (QRT), an estimated $3.21M added.
- The largest Akebia Therapeutics seller in Q1 2024 was Alerce Investment Management, an estimated $4.8M sold.
Based on aggregated 13F filings for Q1 2024.